Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center
Articles by Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center
Jason Luke, MD, FACP, discusses the background of the phase 3 KEYNOTE-716 trial of pembrolizumab vs placebo as adjuvant therapy in patients with stage IIB or IIC melanoma, highlighting previous data from the trial that led to the 36-month follow-up report.
Practical Advice on the Evolving Management of CSCC
ByNikhil Kushalani, MD,Martin Dietrich, MD, PhD,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Vishal A. Patel, MD, FAAD, FACMS Closing out their discussion on the management of cutaneous squamous cell carcinoma, expert panelists share clinical pearls and excitement for the future.
CSCC: Escalating Therapy for High-risk Patients
ByNikhil Kushalani, MD,Martin Dietrich, MD, PhD,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Vishal A. Patel, MD, FAAD, FACMS Dr Vishal Patel shares a surgeon’s perspective on MDC, followed by a discussion on how intensifying treatment after surgery may improve outcomes for higher-risk patients with CSCC.
Best Practices in Multidisciplinary Care for CSCC
ByNikhil Kushalani, MD,Martin Dietrich, MD, PhD,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Vishal A. Patel, MD, FAAD, FACMS Experts in the field of CSCC revisit the concept of multidisciplinary care and consider best communication strategies.
Other Emerging Treatment Modalities in Cutaneous Squamous Cell Carcinoma
ByNikhil Kushalani, MD,Martin Dietrich, MD, PhD,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Vishal A. Patel, MD, FAAD, FACMS Shared insight on novel treatment modalities in the setting of cutaneous squamous cell carcinoma and how they may be triaged moving forward.
CSCC: Translating Cemiplimab Data Into Practice
ByNikhil Kushalani, MD,Martin Dietrich, MD, PhD,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Vishal A. Patel, MD, FAAD, FACMS Following their review of recent clinical data, expert panelists consider how neoadjuvant cemiplimab will fit into the real-world treatment paradigm of resectable CSCC, including the possibility of delaying or avoiding surgery in patients who have an adequate response to cemiplimab.
Neoadjuvant IO Therapy Trials in Resectable CSCC and Cemiplimab Data Updates
ByNikhil Kushalani, MD,Martin Dietrich, MD, PhD,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Vishal A. Patel, MD, FAAD, FACMS A brief overview of clinical trials evaluating the potential use of neoadjuvant immune checkpoint inhibitors—pembrolizumab, atezolizumab, and cemiplimab—in CSCC, followed by a focused discussion of recent cemiplimab trial data.
Lessons Learned in Other Cancers and Suggested Endpoints in Future Trials
ByNikhil Kushalani, MD,Martin Dietrich, MD, PhD,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Vishal A. Patel, MD, FAAD, FACMS Key opinion leaders take time to review how immune checkpoint inhibitors have transformed outcomes in rectal cancer and non-cutaneous squamous cell cancers and consider how to better structure clinical trial endpoints in CSCC.
Clinical Experience With Neoadjuvant IO Therapy in Melanoma
ByNikhil Kushalani, MD,Martin Dietrich, MD, PhD,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Vishal A. Patel, MD, FAAD, FACMS Shared insight on the use of immune checkpoint inhibitors in other patient populations within the skin cancer paradigm, and how lessons may be applied to patients with CSCC.
Evolving Treatment Paradigm of Resectable CSCC
ByNikhil Kushalani, MD,Martin Dietrich, MD, PhD,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Vishal A. Patel, MD, FAAD, FACMS Expert panelists consider the broader evolution of therapy in resectable stage II-IV cutaneous squamous cell carcinoma.
Real World Experience With Resectable Cutaneous Squamous Cell Carcinoma
ByNikhil Kushalani, MD,Martin Dietrich, MD, PhD,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Vishal A. Patel, MD, FAAD, FACMS Expert perspectives on real-world, in-practice identification and management of patients with resectable CSCC.
Staging and Risk Stratification’s Impact on Treatment Approach in CSCC
ByNikhil Kushalani, MD,Martin Dietrich, MD, PhD,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Vishal A. Patel, MD, FAAD, FACMS Panelists round out their review of staging and risk stratification in CSCC by considering how each affects the selection of optimal surgical strategies.
Defining Resectability in CSCC
ByNikhil Kushalani, MD,Martin Dietrich, MD, PhD,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Vishal A. Patel, MD, FAAD, FACMS Following their discussions on staging and risk stratification in CSCC, key opinion leaders work to define resectability in cutaneous squamous cell carcinoma.
Optimal Risk Stratification in Patients With Cutaneous Squamous Cell Carcinoma
ByNikhil Kushalani, MD,Martin Dietrich, MD, PhD,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Vishal A. Patel, MD, FAAD, FACMS Expert panelists share their perspectives on best strategies to risk stratify patients diagnosed with cutaneous squamous cell carcinoma.
Available Staging Systems for Cutaneous Squamous Cell Carcinoma
ByNikhil Khushalani, MD,Martin Dietrich, MD, PhD,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Vishal A. Patel, MD, FAAD, FACMS A review of current staging systems used to categorize CSCC, particularly those from the American Joint Committee on Cancer and Brigham and Women's Hospital.
Cutaneous Squamous Cell Carcinoma: Incidence and Risk Factors
ByNikhil Khushalani, MD,Martin Dietrich, MD, PhD,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Vishal A. Patel, MD, FAAD, FACMS Opening their discussion on resectable cutaneous squamous cell carcinoma (CSCC), expert panelists elucidate its current incidence and known risk factors.
Treatment Optimization for Patients With Melanoma
ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center 
Future Treatment Landscape for Melanoma
ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center 
Promising Late-Stage Trials in Melanoma
ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center 
Targeted Therapy Versus IO for Relapsed/Refractory Melanoma
ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center 
Novel Approaches for Relapsed/Refractory Melanoma
ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center 
Management of Brain Metastases in Melanoma
ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center 
I/O Dosing Schedules in Metastatic Melanoma
ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center 
Novel Therapies for Metastatic Melanoma
ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center 
Systemic Therapy for Metastatic Melanoma
ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center 
Adjuvant Therapy for Melanoma: Safety and Efficacy
ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center 
Adjuvant Therapy for Melanoma: Ongoing Studies of Interest
ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center 
Adjuvant Data Explored for Locally Advanced Melanoma
ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center 
Neoadjuvant Data Explored for Locally Advanced Melanoma
ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center 
pCR and Neoadjuvant Therapy for Melanoma
ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center
